Made available in DSpace on 2014-06-11T19:29:52Z (GMT). No. of bitstreams: 0 Previous issue date: 2008-10-03Bitstream added on 2014-06-13T21:00:22Z : No. of bitstreams: 1 ferreira_egv_me_botfm.pdf: 578426 bytes, checksum: 965dd8dff1cdf74bb54609e4bbb1d19d (MD5) / Financiadora de Estudos e Projetos (FINEP) / Clicar acesso eletrônico abaixo. / Objective: to assess quality of life and psychological aspects in patients with gestational trophoblastic disease (GTD). Methods: This cross-sectional self-report study was carried out among 54 women treated at Botucatu Trophoblastic Diseases Center, São Paulo, Brazil. Validated questionnaires were used to assess quality of life (QoL) (WHOQOL-bref), symptoms of depression (Beck Depression Inventory-BDI) and anxiety (State-Trait Anxiety Inventory –STAI). Results: Most patients rated overall QoL as good (44.44%), and were satisfied with their health status (42.59%). However, these findings did not reach statistical significance. Mean QoL domain score was the highest for psychological health (53.86 ± 21.46), and the lowest for social relationships (65.74 ± 22.41). BDI mean was 15.81 ± 11.15, indicating dysphoria. STAI means were 46 ± 6.46 for trait-anxiety, and 43.72 ± 4.23 for state-anxiety, both evidencing medium-high anxiety. Among patients who were employed, the environment domain mean was the highest (p=0.024). The presence of children prior to disease onset resulted in the lowest means for physical health (p=0,041) and environment (p=0.045). The patients desiring to have children showed significantly higher means for physical health (p=0.004), psychological health (p=0.021) and environment (p=0.003). The need for chemotherapy to achieve complete response had no significant influence on QoL. Conclusion: This study evidenced the psychological impact on GTD patients. This information suggests that specialized care centers should provide psychological interventions during the treatment and follow-up of GTD patients... (Complete abstract click electronic access below)

Objetivo: Comparar características clínicas e resultados de gestações múltipla com mola completa e feto normal coexistente (MHCFC) no New England Trophoblastic Disease Center (NETDC) e em centros de doença trofoblástica (CDT) brasileiros. Métodos: Coorte retrospectiva composta por pacientes com MHCFC provenientes do NETDC (1966-2015) e quatro CDT brasileiros (1990- 2015). Foram realizadas comparações referentes à localização geográfica (NEDTC vs CDT brasileiros), períodos diferentes no NETDC (1966-1989 vs 1990-2015) e quanto evolução para neoplasia trofoblástica gestacional (NTG). Resultados: No período, foram identificados 12.455 casos de doença trofoblástica gestacional, sendo 72 casos de MHCFC inclusos neste estudo. As características clínicas e resultados foram semelhantes entre os casos dos CDT brasileiros (n=46) e NETDC (n=13) entre 1990 e 2015, com exceção de um número significativamente maior de condições potencialmente letais no Brasil (p=0,046). Não houve diferença quanto à apresentação clínica ou aos resultados em dois períodos diferentes no NETDC (13 casos de 1966-1989 vs 13 casos de 1990-2015). Houve 10 casos de interrupção eletiva da gestação (14% das 70 gestações em que o resultado obstétrico estava disponível) e 36 nascimentos de fetos viáveis (60% das 60 gestações nas quais se optou por conduta expectante). A taxa de NTG foi de 46% (31 de 68 casos em que o resultado quanto evolução para NTG estava disponível); os casos que progrediram para NTG apresentaram níveis mais elevados de gonadotrofina coriônica (250.000 mUI/mL vs 120.000 mUI/mL; p=0,026), menor idade gestacional no término da gravidez (17 semanas vs 28,5 semanas; p < 0,001), menor viabilidade fetal (27% vs 69%; p < 0,001), maior taxa de evolução para abortamento espontâneo (35% vs 9%; p=0,020) e mais interrupções da gestação por conta de intercorrências clínicas graves (26% vs 0%; p=0,003). No entanto, a interrupção eletiva da gestação não teve associação com o desenvolvimento de NTG. Conclusões: A maior diferença regional nas MHCFC foi a presença de mais condições potencialmente letais no Brasil. Quando adotada conduta expectante, houve possibilidade de nascimento de feto viável na maior parte das MHCFC. Foi observada elevada taxa de evolução para NTG em MHCFC. A interrupção eletiva da gravidez não influenciou a progressão para NTG, porém interrupções da gestação por complicações clínicas graves, evolução da gestação para abortamento espontâneo, menor idade gestacional no término da gestação, menor viabilidade fetal e níveis elevados de gonadotrofina coriônica foram associados ao desenvolvimento de NTG em MHCFC / Objective: To determine the clinical characteristics and outcomes of multiple pregnancies with complete mole and coexisting normal fetus (CHMCF) in New England Trophoblastic Disease Center (NETDC) and Brazilian trophoblastic disease centers (BTDC). Methods: Retrospective non-concurrent cohorts comprised of CHMCF from NETDC (1966-2015) and four BTDC (1990-2015). Comparisons were made regarding: geographical location from 1990 to 2015 (NETDC vs BTDC), two different periods of time in NETDC (1966-1989 vs 1990-2015) and patients who developed gestational trophoblastic neoplasia (GTN) with the ones that spontaneously regressed. Results: From a total of 12,455 cases of gestational trophoblastic disease seen at the referral centers, 72 CHMCF were identified. Clinical characteristics and outcomes were similar between BTDC (n=46) and NETDC (n=13) from 1990 to 2015, apart from a much higher frequency of potentially life-threatening conditions in Brazil (p=0.046). There were no significant changes in the clinical presentation or outcomes in two different time periods in NETDC (13 cases in 1966-1989 vs 13 cases in 1990-2015). Ten pregnancies were electively terminated (14% of 70 cases with available obstetric outcome) and 36 resulted in viable live infants (60% of 60 pregnancies that were expectantly managed). The rate of GTN was 46% (31 out of 68 cases with available information on GTN development); the cases that progressed to GTN presented with higher chorionic gonadotropin levels (250.000 mIU/mL vs 120.000 mIU/mL; p=0.026), lower gestational age at the end of pregnancy (17 weeks vs 28,5 weeks; p < 0,001), lower fetal viability (27% vs 69%; p < 0,001), higher rate of spontaneous abortions (35% vs 9%; p=0.020) and higher frequency of termination of pregnancy due to medical complications (26% vs 0%; p=0.003) when compared to those with spontaneous remission. However, elective termination of pregnancy was not associated with GTN development. Conclusions: The main regional difference in CHMCF was related to a higher rate of potentially life-threatening conditions in Brazil. Most of the women with CHMCF who were managed expectantly delivered a viable fetus. CHMCF exhibited a high GTN rate. Elective termination of pregnancy did not influence the risk for GTN; however the need for termination due to severe medical complications, spontaneous abortions, lower gestational age at the end of pregnancy, lower fetal viability and higher hCG levels were associated with GTN progression in CHMCF

Objetivo: Comparar características clínicas e resultados de gestações múltipla com mola completa e feto normal coexistente (MHCFC) no New England Trophoblastic Disease Center (NETDC) e em centros de doença trofoblástica (CDT) brasileiros. Métodos: Coorte retrospectiva composta por pacientes com MHCFC provenientes do NETDC (1966-2015) e quatro CDT brasileiros (1990- 2015). Foram realizadas comparações referentes à localização geográfica (NEDTC vs CDT brasileiros), períodos diferentes no NETDC (1966-1989 vs 1990-2015) e quanto evolução para neoplasia trofoblástica gestacional (NTG). Resultados: No período, foram identificados 12.455 casos de doença trofoblástica gestacional, sendo 72 casos de MHCFC inclusos neste estudo. As características clínicas e resultados foram semelhantes entre os casos dos CDT brasileiros (n=46) e NETDC (n=13) entre 1990 e 2015, com exceção de um número significativamente maior de condições potencialmente letais no Brasil (p=0,046). Não houve diferença quanto à apresentação clínica ou aos resultados em dois períodos diferentes no NETDC (13 casos de 1966-1989 vs 13 casos de 1990-2015). Houve 10 casos de interrupção eletiva da gestação (14% das 70 gestações em que o resultado obstétrico estava disponível) e 36 nascimentos de fetos viáveis (60% das 60 gestações nas quais se optou por conduta expectante). A taxa de NTG foi de 46% (31 de 68 casos em que o resultado quanto evolução para NTG estava disponível); os casos que progrediram para NTG apresentaram níveis mais elevados de gonadotrofina coriônica (250.000 mUI/mL vs 120.000 mUI/mL; p=0,026), menor idade gestacional no término da gravidez (17 semanas vs 28,5 semanas; p < 0,001), menor viabilidade fetal (27% vs 69%; p < 0,001), maior taxa de evolução para abortamento espontâneo (35% vs 9%; p=0,020) e mais interrupções da gestação por conta de intercorrências clínicas graves (26% vs 0%; p=0,003). No entanto, a interrupção eletiva da gestação não teve associação com o desenvolvimento de NTG. Conclusões: A maior diferença regional nas MHCFC foi a presença de mais condições potencialmente letais no Brasil. Quando adotada conduta expectante, houve possibilidade de nascimento de feto viável na maior parte das MHCFC. Foi observada elevada taxa de evolução para NTG em MHCFC. A interrupção eletiva da gravidez não influenciou a progressão para NTG, porém interrupções da gestação por complicações clínicas graves, evolução da gestação para abortamento espontâneo, menor idade gestacional no término da gestação, menor viabilidade fetal e níveis elevados de gonadotrofina coriônica foram associados ao desenvolvimento de NTG em MHCFC / Objective: To determine the clinical characteristics and outcomes of multiple pregnancies with complete mole and coexisting normal fetus (CHMCF) in New England Trophoblastic Disease Center (NETDC) and Brazilian trophoblastic disease centers (BTDC). Methods: Retrospective non-concurrent cohorts comprised of CHMCF from NETDC (1966-2015) and four BTDC (1990-2015). Comparisons were made regarding: geographical location from 1990 to 2015 (NETDC vs BTDC), two different periods of time in NETDC (1966-1989 vs 1990-2015) and patients who developed gestational trophoblastic neoplasia (GTN) with the ones that spontaneously regressed. Results: From a total of 12,455 cases of gestational trophoblastic disease seen at the referral centers, 72 CHMCF were identified. Clinical characteristics and outcomes were similar between BTDC (n=46) and NETDC (n=13) from 1990 to 2015, apart from a much higher frequency of potentially life-threatening conditions in Brazil (p=0.046). There were no significant changes in the clinical presentation or outcomes in two different time periods in NETDC (13 cases in 1966-1989 vs 13 cases in 1990-2015). Ten pregnancies were electively terminated (14% of 70 cases with available obstetric outcome) and 36 resulted in viable live infants (60% of 60 pregnancies that were expectantly managed). The rate of GTN was 46% (31 out of 68 cases with available information on GTN development); the cases that progressed to GTN presented with higher chorionic gonadotropin levels (250.000 mIU/mL vs 120.000 mIU/mL; p=0.026), lower gestational age at the end of pregnancy (17 weeks vs 28,5 weeks; p < 0,001), lower fetal viability (27% vs 69%; p < 0,001), higher rate of spontaneous abortions (35% vs 9%; p=0.020) and higher frequency of termination of pregnancy due to medical complications (26% vs 0%; p=0.003) when compared to those with spontaneous remission. However, elective termination of pregnancy was not associated with GTN development. Conclusions: The main regional difference in CHMCF was related to a higher rate of potentially life-threatening conditions in Brazil. Most of the women with CHMCF who were managed expectantly delivered a viable fetus. CHMCF exhibited a high GTN rate. Elective termination of pregnancy did not influence the risk for GTN; however the need for termination due to severe medical complications, spontaneous abortions, lower gestational age at the end of pregnancy, lower fetal viability and higher hCG levels were associated with GTN progression in CHMCF

published_or_final_version / Medical Sciences / Master / Master of Medical Sciences

OBJECTIVES: To determine if women with Human Immunodeficiency Virus infection with severe degrees of immunosuppression are more predisposed to mortality from Gestational Trophoblastic Disease compared with HIV-infected women with less severe degrees of immunosuppression and Human Immunodefiency Virus (HIV) non-infected women. DESIGN: Retrospective review of case records. METHOD: A retrospective review was performed on all patients with Gestational Trophoblastic from 2003 to July 2007. A chart review was conducted and information captured on a data sheet. This retrospective audit was performed at the combined gynaecology oncology clinic of Inkosi Albert Luthuli Central Hospital. All information was kept confidential and was strictly for the purposes of the audit. STATISTICS: Factors associated with mortality were tested using Fisher's exact test. Odds ratios were reported as a measure of the strength of association. Breslow-Day's test for homogeneity in odds ratios was used to compare mortality in HIV-infected and HIV non-infected women. The analysis was done using Stata 9. i RESULTS: A total of 78 patients with Gestational Trophoblastic Disease were reviewed. There were 53 patients with invasive molar pregnancy and 25 patients with choriocarcinoma. The HIV sero-prevalence was 31%. There were 15 deaths (19%). There were 8 HIV-infected (33%o) and 7 HIV non-infected (13%) women who demised. Of the 8 patients with CD4 counts less than 200 cells/ uL, 7 patients demised. There were no mortalities amongst patients with CD4 counts more than 200 cells/uL. Of the 15 deaths, 5 HIV-infected patients and 5 HIV non-infected patients received chemotherapy. There were 5 patients admitted in very poor general condition precluding the administration of chemotherapy. Amongst the 10 patients who received chemotherapy and demised, the causes of death included widespread disease, multiorgan failure and toxicity due to chemotherapy. CONCLUSION: The overall survival of all patients managed with Gestational Trophoblastic Disease was 82% in keeping with the expected high survival reported elsewhere. The majority of patients who demised were admitted in poor general condition and had abnormal blood profiles. Despite resuscitation, these patients failed to improve precluding the administration of chemotherapy which is the mainstay of treatment. Although the numbers are small, there is clear evidence that if patients are HIV-infected with CD4 counts 200 cells/uL despite transient grade 2 myelotoxicity. / Thesis (MMed)-University of KwaZulu-Natal, Durban, 2008.

Thesis (Ph. D.)--University of Missouri-Columbia, 1997. / Typescript. Vita. Includes bibliographical references (leaves 143-164). Also available on the Internet.

Thesis (Ph. D.)--University of Missouri-Columbia, 1997. / Typescript. Vita. Includes bibliographical references (leaves 143-164). Also available on the Internet.

Orientador: Izildinha Maestá / Resumo: Objetivo. Avaliar a influência da contracepção hormonal (HC) no desenvolvimento da agressividade clínica da neoplasia trofoblástica gestacional (NTG) e no tempo para normalização da gonadotrofina coriônica humana (hCG). Desenho do estudo. Coorte retrospectiva. Local do estudo. Centro de Doença Trofoblástica Gestacional do Rio de Janeiro. Pacientes. Pacientes diagnosticadas com gravidez molar. Intervenção. Comparação entre mulheres usuárias de HC ou métodos de barreira (BM) durante todo o acompanhamento da GTD. Desfecho primário. Ocorrência de GTN pós-molar e intervalo para a normalização dos níveis de hCG. Resultados. O uso de HC não influenciou a ocorrência de GTN pós-molar (Odds ratio ajustada - ORa: 0.66, 95% CI: 0.24-1,12, p=0.060), a despeito do tipo de HC utilizada: progesterona isolada (ORa: 0,54, 95% CI: 0.29-1,01, p=0.060) ou contracepção hormonal oral combinada (COC) (ORa: 0.50, 95% CI: 0.27-1.01, p=0.060) ou com diferentes dosagens etinilestradiol, 15mcg (ORa: 1,33, 95% CI: 0.79-2,24, p=0.288), 20mcg (ORa: 1.02, 95% CI: 0.64-1.65, p=0.901), 30mcg (ORa: 1.17, 95%CI: 0.78-1,75, p=0.437) ou 35mcg (ORa: 0.77, 95%CI: 0.42-1,39, p=0.386).O tempo para normalização de hCG ≥ 10 semanas (ORa: 0.58, 95% CI: 0.43-1.08, p=0.071) ou tempo de remissão após quimioterapia ≥ 14 semanas (ORa: 0.60, 95% CI: 0.43-1.09, p=0.067) não diferiram significativamente entre os usuários de HC quando comparadas aos pacientes que utilizam BM, ao controlar outros fatores de risco usando regressão ... (Resumo completo, clicar acesso eletrônico abaixo) / Abstract: Objective. To evaluate the influence of hormonal contraception (HC) on the development and clinical aggressiveness of gestational trophoblastic neoplasia (GTN) and the time for normalization of human chorionic gonadotrophin (hCG) levels. Study design. Retrospective cohort. Setting. Rio de Janeiro Trophoblastic Disease Center. Patient(s). Women diagnosed with molar pregnancy. Intervention(s). Comparison between users of HC or barrier methods (BM) during the postmolar follow-up or postmolar GTN treatment. Main Outcome Measure(s). Occurrence of post-molar GTN and the time for hCG levels normalization. Result(s). The use of HC did not significantly influence the occurrence of postmolar GTN (ORa: 0.66, 95% CI: 0.24-1.12, p=0.060), despite different formulations: progesteroneonly (ORa: 0.54, 95% CI: 0.29-1.01, p=0.060) or combined oral contraception (COC) (ORa: 0.50, 95% CI: 0.27-1.01, p=0.60) or with different dosages of ethinyl estradiol: 15 mcg (ORa, 1.33, 95% CI 0.79-2.24, p=0.288), 20 mcg (ORa: 1.02, 95% CI: 0.64-1.65, p=0.901), 30 mcg (ORa: 1.17, 95% CI: 0.78-1.75, p=0.437) or 35 mcg (ORa: 0.77, 95% CI: 0.42-1.39, p=0.386). The time to hCG normalization ≥ 10 weeks (ORa: 0.58, 95% CI: 0.43-1.08, p=0.071) or the time to remission after chemotherapy ≥ 14 weeks (ORa: 0.60, 95% CI: 0.43-1.09, p=0.067) did not significantly differ among HC users when compared to patients using BM, when controlling for other risk factors using multivariate logistic regression. Conclusion(s). The use... (Complete abstract click electronic access below) / Doutor

Orientador: Izildinha Maestá / Coorientador: Marilza Vieira Cunha Rudge / Coorientador: Rafael Cortés-Charry / Banca: Antônio Rodrigues Braga Neto / Banca: Jurandyr Moreira de Andrade / Resumo: Avaliar o prognóstico da mola hidatiforme (MH) e tratamento da neoplasia trofoblástica gestacional (NTG) pós-molar acompanhadas no Centro de Referência para Doenças Trofoblásticas (CDT) versus outras instituições (OI). Estudo de coorte que incluiu 270 pacientes com MH (204 pacientes acompanhas do CDT-Botucatu, onde essa investigação está sendo realizada, e 66 pacientes inicialmente acompanhadas em OI). Todas as pacientes foram registradas no banco de dados do CDT-Botucatu (Universidade Estadual Paulista, Brasil) entre janeiro de 1990 e dezembro de 2009. O prognóstico da MH, bem como as características da NTG e seu desfecho foram analisados e comparados de acordo com o local de seguimento pós-molar. As seguintes variáveis de confundimento foram incluídas: idade (anos), número de gestação, paridade, número de abortamentos, e o tipo de MH (Completa/Parcial). O desfecho da NTG pós-molar consoante o local de seguimento pós-molar foi comparado utilizando-se o teste de Mann-Whitney, teste do Qui-Quadrado ou teste Exato de Fisher. NTG pós-molar ocorreu em 34 (34/204=16,7%) das pacientes que foram acompanhadas no CDT, e em 27 (27/66=40,9%) daquelas que realizaram o seguimento em OI. Pacientes que foram seguidas no CDT cursaram com características de NTG com melhor prognóstico, tais como: menor índice de metástases (5,8% versus 48%,p=0,003), menor mediana do escore FIGO 2000 [2,00 (1,00; 3,00) versus 4,00 (2,00; 7,00), p=0,003] e início mais precoce da quimioterapia em semanas [7,0 (6,0; 10,0) versus 10,0 (7,0; 16,0), p=0,04]. NTG de alto-risco não foi observada em nenhuma paciente submetida ao EUCDT, ocorrendo em 29% daquelas que foram acompanhadas em OI (p<0,001). Quimioterapia com múltiplos agentes para o tratamento da NTG pós-molar foi necessária em dois casos... (Resumo completo, clicar acesso eletrônico abaixo) / Abstract: To review treatment results of gestational trophoblastic neoplasia (GTN) after hydatidiform mole (HM) evacuation at a referral center (ERC) versus HM evacuation at other institutions (EOI). This cohort study included 270 patients undergoing HM evacuation (204 at the study referral center and 66 at other institutions). All patients were registered in the database of Botucatu Trophoblastic Diseases Center (São Paulo State University, Brazil) between January 1990 and December 2009. GTN characteristics and outcomes were analyzed and compared according to HM evacuation setting. The confounding variables assessed included age (years), number of gestations, parity, number of abortions, and HM type (Complete/Partial). Post-molar GTN outcomes according to HM evacuation setting were compared using Mann-Whitney's test, Chi-square test, or Fisher's exact test. Post-molar GTN occurred in 34 (34/204=16.7%) patients undergoing HM evacuation at the referral center, and in 27 (27/66=40.9%) of those undergoing HM evacuation in other institutions. Patients undergoing HM ERC showed GTN characteristics indicative of better prognosis such as: lower metastasis rate (5.8% versus 48%, p=0.003), lower median FIGO 2000 score [2.00 (1.00; 3.00) versus 4.00 (2.00; 7.00), p=0.003], and earlier chemotherapy onset in weeks [7.0 (6.0; 10.0) versus 10.0 (7.0; 16.0), p=0.04]. High-risk post-molar GTN was observed in no patient undergoing HM ERC, and in 29% of those undergoing HM EOI (p<0.001). Multi-agent chemotherapy for the treatment of post-molar GTN was required in two cases of HM evacuation at the referral center (5.9%) and in eight cases of HM EOI (29.6%) (p=0.017). Median time interval between chemotherapy onset and hCG. normalization in weeks was shorter among patients undergoing HM ERC [9.00 (6.25; 12.0) versus... (Complete abstract click electronic access below) / Mestre

Submitted by RENAN ROCHA SOARES null (rrsoaresmed@bol.com.br) on 2016-04-27T16:57:55Z No. of bitstreams: 1 Tese Doutorado Renan Soares.pdf: 1390332 bytes, checksum: 5a3cf50c9899dc57629c6f4a978b7127 (MD5) / Approved for entry into archive by Felipe Augusto Arakaki (arakaki@reitoria.unesp.br) on 2016-04-29T21:00:38Z (GMT) No. of bitstreams: 1 soares_rr_dr_bot.pdf: 1390332 bytes, checksum: 5a3cf50c9899dc57629c6f4a978b7127 (MD5) / Made available in DSpace on 2016-04-29T21:00:38Z (GMT). No. of bitstreams: 1 soares_rr_dr_bot.pdf: 1390332 bytes, checksum: 5a3cf50c9899dc57629c6f4a978b7127 (MD5) Previous issue date: 2016-02-29 / Apesar de 10 a 34% das pacientes com gravidez molar serem adolescentes, a influencia da idade precoce na apresentação clínica e no risco de desenvolvimento de neoplasia trofoblástica gestacional pós-molar (GTN) ainda é incerto. Objetivos. Comparar a apresentação clínica da mola hidatiforme completa (MHC) e os fatores de risco associados com o desenvolvimento de NTG entre adolescentes da América do Norte e América do Sul. Métodos. Estudo de coorte não concorrente incluindo adolescentes (< 20 anos) com MHC tratadas em centro da América do Norte (New England Trophoblastic Disease Center, Universidade de Harvard, Estados Unidos) entre 1973-2009, e centros da América do Sul (Centro de Doença Trofoblástica de Botucatu – Universidade Estadual Paulista, Unesp, Brazil; Unidade Trofoblástica da Universidade Central da Venezuela e Maternidad Concepción Palácios de Caracas, Venezuela), entre 1990-2009. Dados clínicos das pacientes coletados foram idade, idade gestacional ao diagnóstico, tamanho do útero, hCG pré-esvaziamento, presença de cistos tecaluteínicos, anemia, sangramento vaginal, pré-eclampsia e hiperemese. As participantes do estudo foram alocadas em dois grupos de adolescentes: América do Norte (AN, n = 195) e América do Sul (AS, n = 231). Resultados. Na apresentação, anemia (AS = 48% vs AN = 15%; p <0,001), hiperemese (AS = 14% vs AN = 6%; p = 0,003), e hCG sérico elevado (AS = 229591 mUI / mL vs AN = 14000 mUI / mL; p <0,001) foram mais frequentes na AS que AN. Na AS, pré-eclâmpsia [AS: OR = 4,33 (1,37-13,65) vs AN: OR = 0,34 (0,04-2,86)], tamanho do útero> idade gestacional [AS: OR = 2,50 (1,26-4,94) vs AN: OR = 1,69 ( 0,87-3,26)]; e cistos> 6 cm [AS: OR = 2,25 (0,80-6,33) vs AN: OR = 1,43 (0,57-3,56)] tiveram maior impacto sobre o risco de desenvolver NTG pós-molar. Em contraste, apenas sangramento vaginal. [AS: OR = 1,37 (0,64-2,91) vs AN: OR = 2,79 (1,10-7, 06] influenciou risco de NTG na AN. Conclusões. Comparado à AN, MHC em adolescentes da AS mostraram complicações médicas mais frequentemente e fatores clínicos com maior impacto sobre o risco de desenvolvimento de NTG. / Although 10-34% of patients with molar pregnancy are adolescent, the influence of young age on the clinical presentation and risk of developing post-molar gestational trophoblastic neoplasia (GTN) is still unclear. Objectives. To compare complete hydatidiform mole (CHM) clinical presentation and risk factors associated with developing GTN between North American adolescents and South American counterparts. Methods. Non-concurrent cohort study including adolescents ( 20 years) with CHM referred to centers in North America (New England Trophoblastic Disease Center, Harvard University,USA) between 1973-2009, and South America (Botucatu Trophoblastic Disease Center-São Paulo State University-Unesp, Brazil; Trophoblastic Unit of Central University of Venezuela and Maternidad Concepcion Palacios of Caracas, Venezuela) between 1990-2009. Patient clinical data collected included age, gestational age at diagnosis, uterine size, pre-evacuation hCG, presence of theca lutein cysts, anemia, vaginal bleeding, preeclampsia, and hyperemesis. Study participants were allocated into two groups of adolescents: North American (NA,n=195) and South American (SA,n=231). Results. At presentation, anemia (SA=48% vs NA=15%;p<0.001), hyperemesis (SA=14% vs NA=6%;p=0.003), and elevated serum hCG (SA=229591 mUI/mL vs NA=14000 mUI/mL ; p<0.001) were more frequent in SA than in NA. In SA, preeclampsia (SA:OR=4.33(1.37-13.65) vs NA:OR=0.34(0.04- 2.86), uterine size>gestational age (SA:OR= 2.50(1.26-4.94) vs NA: OR=1.69(0.87- 3.26); and cysts > 6cm (SA: OR= 2.25(0.80-6.33) vs NA:OR=1.43(0.57-3.56) had greater impact on the risk of developing post-molar GTN. In contrast, only vaginal bleeding (SA:OR=1.37(0.64-2.91) vs NA: OR=2.79(1,10-7, 06) influenced GTN risk in NA. Conclusions. Compared to NA, CHM among SA adolescents showed medical complications more frequently, and clinical features with greater impact on risk of GTN development.